| Previous Close | 32.67 |
| Open | 32.60 |
| Bid | 32.75 x 100 |
| Ask | 32.85 x 400 |
| Day's Range | 32.32 - 32.87 |
| 52 Week Range | 29.83 - 35.38 |
| Volume | 16,934,236 |
| Avg. Volume | 18,464,160 |
| Market Cap | 195.51B |
| Beta | 1.05 |
| PE Ratio (TTM) | 27.58 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.92%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
Capital Cube•9 hours agoPfizer Inc. :PFE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 21, 2017
Categories: Yahoo FinanceGet free summary analysis Pfizer Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Pfizer Inc. – Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Mylan N.V., ... Read more (Read more...)
- Motley Fool•11 hours ago
Better Buy: AbbVie Inc. vs. Pfizer Inc.
AbbVie and Pfizer both have great dividends and successful track records over the long run. But which is the better pick now?
- Motley Fool•yesterday
Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant
Besponsa's FDA approval for use in some leukemia patients continues to position the company as a leading player in cancer treatment.
